The 2017 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2017 News Archive

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Stevenage, UK -  10 July 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted AUT00206 an Orphan Drug Designation for the treatment of Fragile X Syndrome, the most common known cause of inherited learning disabilities.

Read more


Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

Stevenage, UK -  18 May 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.

Read more


Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

London, UK -  15 March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.

Read more


Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

London, UK -  10 January 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced positive findings from a Phase Ia clinical trial of AUT00206, a first-in-class Kv3 modulator in development for the treatment of schizophrenia, as well as the start of the first of two Phase Ib studies with the molecule.

Read more